logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: News & Comments

XyloCor Therapeutics Reported Positive Safety and Efficacy Results of XC001 Novel Gene Therapy for Refractory Angina

XyloCor Therapeutics Announced Positive Results for XC001 XyloCor Therapeutics announced the completion of the Phase 2 portion of its Phase 1/2 clinical trial ( EXACT ) designed to assess the safety and preliminary evidence of efficacy of lead gene therapy candidate XC001...

Read More

January 27, 2023

0

The U.S. FDA Approved Johnson & Johnson AKEEGA™ for BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

Johnson & Johnson's Janssen Pharmaceutical AKEEGA Johnson & Johnson ( JNJ )  owned Janssen Pharmaceutical announced that the U.S. FDA has approved AKEEGA™ (niraparib and abiraterone acetate), the first-and-only dual action tablet combining a PARP inhibitor with abiraterone acetate, given with...

Read More

August 15, 2023

0

As Expected, Seagen Was Taken Over, the Buyer is Pfizer.

Pfizer to Acquire Seagen Pfizer ( PFE ) is to acquire Seagen ( SGEN ) for $229 per share in cash, for a total enterprise value of approximately $43 billion Dr. Albert Bourla, Pfizer Chairman and Chief Executive Officer, said,...

Read More

March 13, 2023

0

23andMe Teams Up with Novartis on Lipoprotein(a) Education for its Customers

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. ( ME ) announced a collaboration with Novartis Pharmaceuticals Corporation...

Read More

March 24, 2023

0

New Study from Neuvivo’s NP001: First to Link Regulation of the Innate Immune System with Respiratory Function in ALS

New Study from Neuvivo On March 30, 2023,  Neuvivo - a private Company, announced the publication of a peer-reviewed paper in ' Cells ' titled: “ Regulation of the Innate Immune System as a Therapeutic Approach to Supporting Respiratory Function...

Read More

March 31, 2023

0

TRxADE HEALTH Subsidiary, Bonum Health, Signed a Telemedicine Service Distribution Deal with Big Y Pharmacy. See Also: Innate Pharma

TRxADE HEALTH Inc TRxADE HEALTH Inc ( MEDS ) is a health service IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey, and patient engagement in the U.S.. The firm operates the TRxADE...

Read More

July 1, 2021

0

Why Celldex Therapeutics Stock is Soaring

Celldex Therapeutics is Soaring Celldex Therapeutics ( CLDX ) stock soared following the firm’s announcement of updated data from its ongoing, open-label Phase 1b clinical trial of CDX-0159 in patients with antihistamine refractory cold urticaria and symptomatic dermographism, which are...

Read More

July 11, 2021

0

Immunome Inc Stock Rallied After Announcing it Neutralized the SARS-CoV-2 Delta Variant.

Immunome Inc: Neutralizing SARS-C0V-2 Delta Variant Immunome Inc ( IMNM ) is a small biotech firm whose stock soared after announcing today that its three-antibody cocktail ( IMM-BCP-01 ) demonstrated potent neutralizing activity against the SARS-CoV-2 (the virus that cause...

Read More

July 20, 2021

0

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

May 01, 2023 (GLOBE NEWSWIRE) –Today, Intellia Therapeutics (NTLA) released its 2023 Corporate Responsibility report. The report provides a comprehensive update of the Company’s performance and progress across key Environmental, Social and Governance (ESG) areas of focus. John Leonard, M.D.,...

Read More

May 1, 2023

0

Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam

Cassava Sciences: Positive Clinical Data with SavaDX Cassava Sciences ( SAVA ) today announced positive clinical data with SavaDx, an investigational diagnostic/biomarker to detect Alzheimer’s disease with a simple blood test. SavaDx was used to measure plasma levels of altered filamin...

Read More

July 26, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 106
  • 107
  • 108
  • ...
  • 115
  • 116
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy